Imagene AI was founded in 2020 with a clear mission, to assist cancer patients in receiving the optimal treatment medicine can offer.
We are leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from the biopsy image alone. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.
Through collaborations with top-tier medical centers and pharmaceutical companies, Imagene is revolutionizing molecular screening for both clinical practice and research.
Our success derives from our cutting-edge technology and talented multidisciplinary team of data scientists, biologists, software engineers, and medical experts.
Cancer diagnostic focus on pathological and molecular testing. Both are conducted by advanced technology which depends on limited amount of tissue, and therefore does not allow wide and extensive diagnosis. Further, genomic analysis, infrastructure and personnel are highly expensive and the overall diagnosis require prolong time to report. These four factors can be improved significantly with in silico and AI based algorithms.
We believe that no structure and assumptions should become a barrier to personal treatment. Imagene brings the potential of accurate, fast, low cost, actionable, standardized, and routine screening to all cancer patients
